Gritstone and the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, have entered into a clinical trial agreement to initiate clinical testing. Under the terms of the collaboration agreement, NanoString will develop, seek regulatory approval for, and commercialize the diagnostic test and is eligible to receive payments totaling up to $45 million of which $5. Completion of the CB 2679d/ISU304 toxicology studies supported the recent Investigational New Drug (IND) approval by the Korean Ministry of Food and Drug Safety (MFDS) and triggered a milestone payment to Catalyst.
Catalyst Biosciences, Inc. recently announced it has achieved a financial milestone under its collaboration with ISU Abxis. The combined company is named Ocera Therapeutics, Inc. and will trade beginning July 16, 2013 on the NASDAQ Global Market under the symbol OCRX. HOOKIPA Pharma Inc. recently announced the first patient has been dosed with HB-200 in combination with pembrolizumab for the treatment of first-line advanced/metastatic Human Papillomavirus 16…. Alenura is a patented, innovative, clinical-stage bladder instillation product candidate that combines lidocaine, a well-established anaesthetic, in a new alkalinized form with heparin, a component of mucous membranes. Our aim will be to identify which patients could benefit from a treatment involving SGK1 inhibitors using precision medicine tools that have become recently available. Nabriva Therapeutics AG recently announced it has completed enrollment in its first lefamulin evaluation against pneumonia (LEAP 1) Phase 3 clinical trial. RVX News Today | Why did Resverlogix stock go down today. OMS201 is a proprietary combination of an anti-inflammatory agent and a smooth muscle relaxant, each with well-known safety and pharmacologic profiles.
This new partnership builds on biology insights in the field of transcriptional regulation from the work of Prof. Conatus Pharmaceuticals Inc. recently announced that its exclusive license with Novartis for the global development and commercialization of emricasan has become effective under terms of the Option, Collaboration, and License Agreement signed in December 2016. Mithra Pharmaceuticals recently announced an exclusive long-term license and supply agreement that extends beyond 10 years with Mayne Pharma, a leading specialty pharmaceutical company, for the commercialization in the US of Myring, Mithra's combined hormonal contraceptive vaginal ring made of ethylene vinyl acetate copolymers (EVA). ADCT-402, an ADC designed to target and kill CD19-expressing malignant B-cells, is also being evaluated in an ongoing pivotal Phase II clinical trial in patients with relapsed or refractory (R/R) DLBCL and a Phase I clinical trial in combination with IMFINZI (durvalumab) in patients with multiple types of R/R non-Hodgkin lymphoma. Vaxxinity, Inc. recently announced the first subjects have been dosed in a Phase 1 clinical trial of UB-313, a vaccine targeting calcitonin gene-related peptide (CGRP), for the preventive treatment of migraine. Apellis Pharmaceuticals, Inc. and Affilogic recently announced the companies have expanded their research and development (R&D) collaboration, which was initially formed in 2018, to include the development of Nanofitins…. EXECUTIVE INTERVIEW – Norwich Pharma Services: Synchronized Outsourced Solutions for Contract Development & Manufacturing. Nkarta Therapeutics Reports Potent Natural Killer Cell Anti-Cancer Activity in Preclinical Tumor Model. The results were presented in a poster session entitled: A Phase 1 Study of PolyPEPI1018 Vaccine Plus Maintenance Therapy in Patients with Metastatic Colorectal Cancer with a Predictive Biomarker (OBERTO) at the 2019 American Society of Clinical Oncology (ASCO) annual meeting in Chicago on June 3. "This merger has significantly broadened the opportunities we can pursue, spanning from the discovery of new molecules through clinical development, " said Peter Grebow, The Gene Editing Institute of Christiana Care's Helen F. Resverlogix announces appointment of new chief scientific officer in chinese. Graham Cancer Center & Research Institute Signs Agreement With ABS.
The Phase III trial results revealed that neratinib, also known as PB272, improved disease-free survival for women with early stage, HER2-positive breast cancer by 33% compared with placebo after adjuvant treatment with Herceptin, also known as trastuzumab. This represents the first option exercised under the companies' oncology target discovery and validation collaboration established in 2013. Eyenovia, Inc. recently announced that the company successfully completed a Type A meeting with the US FDA related to the refiling of the NDA for MydCombi. 1 billion by 2022, at a relatively strong compound annual growth rate of 4. The international Phase 2b trial is approximately 75% enrolled as of this date. EG-1962, the company's lead product candidate, is in development to treat patients who have suffered an aneurysmal subarachnoid hemorrhage (aSAH) resulting from a ruptured brain aneurysm. The technology will also facilitate fast and efficient scale up and transfer of powder-fill formulations within Capsugel's global network of commercial production sites. Valneva SE and Pfizer recently announced the initiation of a Phase 3 clinical study, Vaccine Against Lyme for Outdoor Recreationists (VALOR) (NCT05477524), to investigate the efficacy, safety and…. Athira Pharma Announces Initiation of Patient Dosing in SHAPE, a Phase 2 Clinical Trial of ATH-1017 for the Treatment of Parkinson's Disease Dementia & Dementia with Lewy Bodies. Resverlogix announces appointment of new chief scientific office de. There are three positions that you can take in making a business decision: 1) make no decision (worst); Infections by Human Cytomegalovirus (HCMV) are among the medically most significant herpesvirus infections. A self-selection study ensures that consumers can make appropriate decisions based on their own personal health circumstances about whether to use a particular drug product. The Biologics License Application (BLA) for the liquid frozen formulation of MVA-BN is currently under review at the FDA, Aclaris Therapeutics, Inc. recently announced positive results from a Phase 2 open-label clinical trial of ATI-502 (AGA-201), an investigational topical Janus Kinase (JAK) 1/3 inhibitor, in patients with androgenetic alopecia (AGA), a condition commonly known as male/female-pattern baldness. BASF and PETRONAS Chemicals Group Berhad intend to invest $500 million in an integrated aroma ingredients project at their existing joint venture site BASF PETRONAS Chemicals in Gebeng, Kuantan.
THE EVOLUTION OF IMMUNOTHERAPIES. All five countries have granted the company a patent with multiple claims. Results showed that SPR206 was generally well-tolerated with a mean lung epithelial lining fluid (ELF) to plasma concentration ratio of 0. Catalent recently announced the launch of its new Xpress Pharmaceutics service, designed to accelerate the development of oral drugs through Phase 1 clinical studies. The milestone is a result of Avanir initiating dosing of patients in a Phase III clinical trial with AVP-786 for the treatment of agitation in patients with Alzheimer's disease. Existing investors in Rani Therapeutics include Novartis, Google Ventures, Buttonwood, GF Ventures, KPC Pharmaceuticals, InCube Ventures, and VentureHealth, among others. Amyris, Inc. recently announced it successfully delivered on its first milestone for its cannabinoid partner, LAVVAN, earning its first payment of $10 million, which is part of a $300-million collaboration before future royalty payments. ImmunoGen Announces a Global, Multi-Target License & Option Agreement With Vertex for the Use of ImmunoGen's ADC Technology in the Development of Novel Targeted Conditioning Agents. Avacta's tumour microenvironment activated drug conjugates (TMAC) are a groundbreaking new form of cancer immunotherapy, combining its Affimer biotherapeutics with chemotherapies in a single drug, using a linker (incorporating its proprietary pre|CISION substrate) that is designed to only release the chemotherapy in the tumour microenvironment through the action of an extracellular enzyme called FAPa. Philadelphia, PA, December 16, 2014: Hemispherx Biopharma, Inc. Resverlogix announces appointment of new chief scientific officer duties. (NYSE MKT: HEB) (the "Company" or "Hemispherx"), recently announced further progress on developing Ampligen® (rintatolimod) as a potential therapeutic complement to a new molecular class of anti-tumor drugs termed immune checkpoint inhibitors or PD-1 inhibitors (also called Programmed Death inhibitors). Emisphere Technologies, Inc. and Novo Nordisk A/S recently announced they have entered into an exclusive development and license agreement to develop and commercialize oral formulations of Novo Nordisk's insulins, which have the potential of treating diabetes, using Emisphere's Eligen Technology. The increased capacity further enhances Vibalogics' flexibility, minimizing time to clinic for its clients. Gerresheimer is combining its expertise into a specialized team called Gx Solutions, an interdisciplinary expert and sales team able to utilize the development know-how of four Technical Competence Centers. Working in partnership, Catalent and Zumutor have created a fucose knockout GPEx cell line expressing high levels of an anti-HER2 antibody.
This addition is driven by the increased global demand for animal-free consumer health products, and these new lines will be completed by September 2019. SeraNovo B. recently announced it has signed a second License Agreement with Carna Biosciences, Inc., a company engaged in the drug development of…. Drug Discovery Science News | Page 853 | Technology Networks. If approved, etranacogene dezaparvovec will provide people living with hemophilia B in the European Union (EU) and European Economic Area (EEA) with the first-ever gene therapy treatment option that significantly reduces the rate of annual bleeds after a single infusion. What if you could employ a new, patented technology that may make these treatments possible? Derek G. Hennecke continues with part 2 of his 6-part series on lessons learned from other industries. Cancer Genetics is a leader in drug discovery and….
Under the terms of the agreement, Catalent will purchase the shares of SCTS, currently held by Bone Therapeutics, which owns and operates a purpose-built CGxP facility of approximately 41, 000 square-foot (3, 800 square-meter), XOMA Corporation recently announced NIS793, an anti-TGFβ monoclonal antibody licensed from XOMA, has advanced to the Phase 2 development stage, triggering a $25-million milestone payment from Novartis. PhoreMost Limited and Polaris Quantum Biotech recently announced a collaboration to study oncology targets currently considered undruggable. This breakthrough biotech collaboration was initially announced on June 29, 2016 and, upon board approval, both companies plan to move quickly to establish a leading position within the market for sustainable, » Read more about: Amyris & Ginkgo Bioworks Complete Collaboration Agreement to Accelerate Commercialization of Bio-Based Products ». "Our commitment to advancing the science of immuno-oncology includes pursuing cutting-edge RNA and DNA approaches to identify a range of biomarkers, IGI Laboratories, Inc. recently announced it has submitted its third abbreviated new drug application (ANDA) to the US Food and Drug Administration (FDA) of 2015, which brings the company's total number of ANDA submissions now pending at the FDA to 25. THERAPEUTIC FOCUS – Therapeutic Advances in Non-Small Cell Lung Cancer: Targeting Activating & Resistant Forms of EGFR & ALK. Oramed Pharmaceuticals Inc. recently announced the treatment of the last patient in the primary cohort of the Phase 2b HbA1c trial evaluating Oramed's lead oral insulin candidate, ORMD-0801, which has the potential to be the first commercial oral insulin capsule for the treatment of Type 2 diabetes. The highest dose tested, SB206 12%, demonstrated a statistically significant improvement (p<0. "The adoption of the Cira platform by ABL represents another important step towards strong market adoption of our highly sensitive, multiplexing detection system for clinical applications, " said Susan Vogt, Intellia Therapeutics Demonstrates Sustained & Durable Genome Editing With CRISPR/Cas9 in 1-Year Animal Study. "Immune checkpoint inhibitors are making a profound impact in the treatment of people with cancer, " said Sean McCarthy, Catalent Pharma Solutions and Vaccinex, Inc. recently announced an agreement to develop an antibody-drug conjugate (ADC) using Catalent's proprietary SMARTag® conjugation platform and GPEx® cell line engineering technologies, and Vaccinex's proprietary ActivMAb® technology. "As the majority of cases have progressed to an advanced stage, Catalent Increases Specialized Packaging Capabilities at its Philadelphia Facility to Support Growing Biologic & Cell & Gene Therapy Markets. PDS0101 in combination with KEYTRUDA is being studied in the VERSATILE-002 Phase 2, open-label, multicenter trial for the treatment of recurrent or metastatic HPV16-positive head and neck cancer in collaboration with Merck (known as MSD outside the US and Canada). The poster, titled CLR 131 Demonstrates High Rate of Activity in a Phase 1, Dose Escalation Study in Patients with Relapsed or Refractory Multiple Myeloma (RRMM) highlights data from 4 subjects in Cohort 6 who received a fractionated dose of 37. Akston Biosciences Corporation recently announced it dosed the first set of volunteers in an open-label study of AKS-452, its protein subunit COVID-19 vaccine, as a booster. "We are extremely pleased with the emerging clinical profile of OP-1250 and the encouraging progress achieved over the last six months.
Crown Bioscience recently announced it has enhanced its existing platform for chimeric antigen receptor (CAR) T-cell agent evaluation with bioluminescent imaging capabilities. The identity of the pharmaceutical company and its target therapy, which is approved in the US and Europe for the treatment of a high prevalence disease of the retina, will remain confidential at this time to protect the commercial interests of the customer. Decibel Therapeutics recently announced the presentation of preclinical data on its lead gene therapy product candidate, DB-OTO, as well as preclinical data highlighting the identification of proprietary, cell-selective promoters…. The healthcare landscape continues to change at a rapid pace.
MPhase recently filed a United States Letter Patent application for its novel drug delivery system based on its Smart Surface technology. The company will be a wholly owned subsidiary of Nanobiotix and operate in France and in the US with a dedicated team committed to growth and potential financing opportunities. ABITEC Corporation, a global manufacturer of specialty lipids, has executed a multi-year agreement with distribution partner DKSH to market and sell its ingredients into select markets. Tipifarnib is an inhibitor of farnesylation, a key cell-signaling process implicated in cancer initiation and development.